Exploratory Analysis of PET and CA 19-9 Response in Pancreatic Ductal Adenocarcinoma Outcomes: A Secondary Analysis of a Prospective Phase 2 Trial
Keaton Rummel(University of North Dakota), Krishan R. Jethwa(Mayo Clinic), J.B. Ashman(Mayo Clinic Hospital), Rotonya M. Carr(University of Pennsylvania), Mark J. Truty(Mayo Clinic in Arizona), William G. Rule(Mayo Clinic in Arizona), William S. Harmsen(Mayo Clinic), Cornelius A. Thiels(Mayo Clinic in Arizona), Christopher L. Hallemeier(Mayo Clinic in Arizona), Cameron M. Callaghan(Mayo Clinic in Arizona), Michael G. Haddock(Mayo Clinic in Arizona), Tanios Bekaii‐Saab(WinnMed), Ajit H. Goenka(Mayo Clinic in Arizona), Kenneth W. Merrell(Mayo Clinic), M.A. Timm(Mayo Clinic in Arizona), T.T.W. Sio(Mayo Clinic Hospital), Chee-Chee Stucky(WinnMed), Robert R. McWilliams(Mayo Clinic in Arizona)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2025
Cited by 0
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer
|Nature Genetics|2009|724